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Background
Very little clinical research has been
conducted on how to manage children
withseveremalaria,despiteitaccounting
for the deaths of around 1 million
children each year in Africa alone.
Antimalarial drugs remain the mainstay
of treatment (and are the subject of
several current or planned clinical trials),
but there is increasing debate around
aspects of supportive care and the
treatment of complications. No aspect of
care has been more controversial in
recent years than the initial ﬂuid
management of children with severe
malaria, particularly given the resource-
poor health-care context in which most
such children are treated. The debate
centres around the role of hypovolaemia
(i.e., insufﬁcient circulating blood volume)
in the pathophysiology of severe malaria.
Hypovolaemia has been incriminated as
an important cause of metabolic acidosis,
which has been shown repeatedly to be
associated with a poor prognosis. The key
question is whether hypovolaemia
contributes to impaired tissue perfusion
in severe malaria, contributing to the
anaerobic glycolysis and consequent
acidosis. Some studies of severe malaria
inchildrenhavesupportedthishypothesis
by providing indirect evidence (e.g.,
capillary reﬁll time, central venous
pressure measurements, raised
creatinine, and clinical dehydration) that
severely ill patients are commonly
hypovolaemic on admission, and that this
contributes to the severity of the disease
[1,2]. In febrile children hypovolaemia
often results from dehydration, but a
detailed study in Gabon showed that the
children with severe malaria investigated
had only a mild or moderate degree of
dehydration (as measured by total body
water, not necessarily synonymous with
hypovolaemia) [3]. So, should children
with severe malaria all receive rapid
intravenous ﬂuid rehydration? And if so,
with what ﬂuid?
Proponents of rapid ﬂuid repletion cite
the standards of care applied in resource-
rich settings for severely ill children with
bacterial sepsis, whilst those advocating
caution argue that malaria should be
considered differently, particularly given
the haemodynamic and circulatory
differences from sepsis and the concerns
of precipitating or worsening pulmonary
or cerebral oedema [2,4].
It is clear that clinical trials are the only
way forward to resolve the debate. There
have been several previously published
intervention studies, all conducted by
Maitland and the Kiliﬁ team on the
Kenyan coast, but to date all have been
too small and heterogenous to provide
conclusive answers.
Should children with
severe malaria all
receive rapid
intravenous fluid
rehydration? And if so,
with what fluid?
The largest of these studies did provide,
in a sub-group analysis of severely
acidotic patients, a tantalising suggestion
of a mortality beneﬁt from ﬂuid resusci-
tation with albumin 4.5%, when com-
p a r e dw i t hs a l i n e .B u tt h e r ew a sn o
‘‘maintenance ﬂuids only’’ control group,
and as mortality was relatively high in the
saline group, a deleterious effect of saline
bolus could not be excluded. There is,
however, a scientiﬁc rationale suggesting
that albumin might possibly be beneﬁcial
in severe malaria, as it has been shown to
have a number of physiological effects
other than on colloid oncotic pressure.
In particular, there is recent evidence
that albumin may be neuroprotective in
acute ischemic stroke [5].
The Study’s Key Findings
Akech et al. have conducted a phase II study
[6] examining the safety and efﬁcacy of ﬂuid
resuscitation with Gelofusine (a gelatin-
b a s e ds y n t h e t i cc o l l o i d )a n dw i t ha l b u m i n
in 88 children with severe malaria and
metabolic acidosis but without severe
anaemia. Sixty percent of the patients had
cerebral malaria. In terms of safety it was
reassuring that no patients developed
pulmonary oedema, and only two
developed clinical signs of raised
intracranial pressure (both in the
Gelofusine group).
Though there was no difference
between the two groups in terms of the
primary outcomes, resolution of shock
and of acidosis, there was a suggestion on
analysis of the secondary outcomes of a
mortality beneﬁt in favour of albumin (p
¼ 0.06). In addition, the authors pool the
data from all their trials comparing
albumin with other resuscitation ﬂuids,
and ﬁnd that albumin administration is
associated with a very signiﬁcant overall
mortality beneﬁt.
Limitations of This Study
In this phase II study, patients were not
individually randomised but rather
allocated to the treatments in blocks of
ten, though it appears from the baseline
data that the resulting two groups were
evenly matched. This has no implications
for the safety data, but puts limitations on
the interpretation of the mortality data.
In addition, mortality was not a primary
endpoint for either this study or any of
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analysis, so the ﬁnding of a mortality
beneﬁt from albumin administration
should be regarded as hypothesis-
generating rather than deﬁnitive, despite
the impressive p-value (p ¼ 0.004).
Although the safety data are reassuring,
the lack of a ‘‘maintenance ﬂuids only’’
control group limits the study’s impact on
the overall debate over whether aggressive
ﬂuid resuscitation should be given at all.
Implications for Future Research
Give that severe malaria is such an
important disease in terms of morbidity
and mortality throughout the tropical
world, it is astonishing how few clinical
trials have addressed its treatment.
This is particularly true for the
non-antimalarial-drug aspects of
management; few trials have been
carried out, and those that exist have
often been inadequately powered and of
poor quality [7]. No adjunctive therapy
has ever been shown to be beneﬁcial.
Akech and colleagues are to be
congratulated for pursuing practical
clinical answers to how the management
of severe malaria in Africa can be
improved. Out of their work and that of
others in the ﬁeld, including those who
oppose aggressive ﬂuid resuscitation, two
separate but interconnected clinical
questions arise. Firstly, is aggressive ﬂuid
therapy in severe childhood malaria
indicated? Secondly, does ﬂuid
resuscitation with albumin have speciﬁc
beneﬁts, such as a neuroprotective effect
in comatose patients? Only large,
adequately powered, probably multi-
centre, randomised clinical trials can
answer these questions. Surrogate
markers, such as resolution of acidosis
(despite its central role in the original
hypothesis), have not been proven to be
linked with mortality. The current study
provides safety data to support a large
trial of ﬂuid resuscitation, as well as
providing hypothesis-generating data to
support inclusion of albumin as an arm in
such a trial. Although albumin is
prohibitively expensive by African
health-care standards (about US$35 per
treatment), with the planned widespread
use of long-term antiretroviral therapy in
Africa the accepted precedents are
changing, and cost should not be a
reason to exclude albumin from
assessment. Any study must have a
‘‘maintenance ﬂuids only’’ control arm,
as the risk–beneﬁt ratio of ﬂuid
resuscitation per se, particularly with
saline, remains unclear. The debate on
ﬂuid management is a healthy one, and
the few groups working in this ﬁeld
should work together to produce a
clinical trial design that will answer
these important questions. The potential
beneﬁts for African children with severe
malaria are enormous. “
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